ArticleCancer reports (Hoboken, N.J.)2026
Patients With Stage III PLCNEC Advocated for Radiotherapy Combined With Chemotherapy While With Stage IV Focus on Individualized Management: Evidence From SEER.
Article in Cancer reports (Hoboken, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPLCNEC is a rare and highly aggressive lung cancer with a poor prognosis. Multimodal therapy, primarily chemotherapy-based, is the standard for advanced PLCNEC, but the role of radiotherapy remains unclear.
methodsWe analyzed 1086 PLCNEC patients receiving chemotherapy from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2015. Propensity score matching (PSM) was applied to adjust baseline confounding variables. Kaplan-Meier survival curves were constructed and compared to assess survival differences. Cox proportional hazards regression models were employed to evaluate prognostic factors. Predictive nomograms were developed and validated to predict individual survival probabilities and facilitate clinical decision-making.
resultsChemotherapy combined with radiotherapy was associated with improved OS and CSS compared with chemotherapy alone in stage III-IV PLCNEC patients (p < 0.05). Sex, N stage, M stage, surgical treatment, and radiotherapy were identified as independent prognostic factors. Nomograms developed demonstrated strong predictive performance, with areas under the curve (AUCs) for OS of 0.720, 0.821, and 0.847 at 1, 3, and 5 years, respectively, and for CSS of 0.733, 0.800, and 0.810 at the corresponding time points. Subgroup analyses suggested that selected patients may derive differential benefit from chemoradiotherapy.
conclusionRadiotherapy is associated with improved survival outcomes in stage III PLCNEC patients receiving chemotherapy, whereas its role in stage IV disease appears more context-dependent and warrants individualized consideration. The proposed nomograms provide complementary prognostic information to support individualized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.